Pathogenic CD8(+) T cells in multiple sclerosis.
Traditionally, autoimmune pathogeneses have been attributed to CD4(+) T lymphocytes, as in multiple sclerosis (MS), rheumatoid arthritis, type 1 diabetes mellitus, and/or to B lymphocytes, as in myasthenia gravis and systemic lupus erythematosus. That is because their primary genetic associations ar...
| Main Authors: | , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2009
|
| _version_ | 1797101573364514816 |
|---|---|
| author | Friese, M Fugger, L |
| author_facet | Friese, M Fugger, L |
| author_sort | Friese, M |
| collection | OXFORD |
| description | Traditionally, autoimmune pathogeneses have been attributed to CD4(+) T lymphocytes, as in multiple sclerosis (MS), rheumatoid arthritis, type 1 diabetes mellitus, and/or to B lymphocytes, as in myasthenia gravis and systemic lupus erythematosus. That is because their primary genetic associations are mostly with certain human leukocyte antigen class II alleles, whose gene products present antigens to CD4(+) T cells. Because few autoimmune diseases show stronger associations with major histocompatibility complex class I alleles (ankylosing spondylitis, Behçet's disease, and psoriasis), CD8(+) T cells, which interact with major histocompatibility complex class I molecules, have been largely ignored in autoimmunity research. However, a variety of findings has recently revived interest in this population, particularly in MS. First, it shows associations with major histocompatibility complex class I alleles. Second, its lesions show a predominance of CD8(+) T cells. Third, these represent effectors that can directly damage central nervous system target cells. Furthermore, several clinical trials of monoclonal antibodies specifically against CD4(+) T cells, or the polarizing cytokines on which they depend, have failed to show any therapeutic benefit in MS, unlike broader-spectrum antibodies that deplete all T cells. Here, we review the evidence that CD8(+) T cells play a role in MS pathogenesis. |
| first_indexed | 2024-03-07T05:53:46Z |
| format | Journal article |
| id | oxford-uuid:e9ceba3c-b003-48bd-8b15-ea963824dcf6 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T05:53:46Z |
| publishDate | 2009 |
| record_format | dspace |
| spelling | oxford-uuid:e9ceba3c-b003-48bd-8b15-ea963824dcf62022-03-27T10:57:02ZPathogenic CD8(+) T cells in multiple sclerosis.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:e9ceba3c-b003-48bd-8b15-ea963824dcf6EnglishSymplectic Elements at Oxford2009Friese, MFugger, LTraditionally, autoimmune pathogeneses have been attributed to CD4(+) T lymphocytes, as in multiple sclerosis (MS), rheumatoid arthritis, type 1 diabetes mellitus, and/or to B lymphocytes, as in myasthenia gravis and systemic lupus erythematosus. That is because their primary genetic associations are mostly with certain human leukocyte antigen class II alleles, whose gene products present antigens to CD4(+) T cells. Because few autoimmune diseases show stronger associations with major histocompatibility complex class I alleles (ankylosing spondylitis, Behçet's disease, and psoriasis), CD8(+) T cells, which interact with major histocompatibility complex class I molecules, have been largely ignored in autoimmunity research. However, a variety of findings has recently revived interest in this population, particularly in MS. First, it shows associations with major histocompatibility complex class I alleles. Second, its lesions show a predominance of CD8(+) T cells. Third, these represent effectors that can directly damage central nervous system target cells. Furthermore, several clinical trials of monoclonal antibodies specifically against CD4(+) T cells, or the polarizing cytokines on which they depend, have failed to show any therapeutic benefit in MS, unlike broader-spectrum antibodies that deplete all T cells. Here, we review the evidence that CD8(+) T cells play a role in MS pathogenesis. |
| spellingShingle | Friese, M Fugger, L Pathogenic CD8(+) T cells in multiple sclerosis. |
| title | Pathogenic CD8(+) T cells in multiple sclerosis. |
| title_full | Pathogenic CD8(+) T cells in multiple sclerosis. |
| title_fullStr | Pathogenic CD8(+) T cells in multiple sclerosis. |
| title_full_unstemmed | Pathogenic CD8(+) T cells in multiple sclerosis. |
| title_short | Pathogenic CD8(+) T cells in multiple sclerosis. |
| title_sort | pathogenic cd8 t cells in multiple sclerosis |
| work_keys_str_mv | AT friesem pathogeniccd8tcellsinmultiplesclerosis AT fuggerl pathogeniccd8tcellsinmultiplesclerosis |